Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. - Wikidata - wikimedia - TriplyDB

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33401018

about

Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatment Elotuzumab for the treatment of multiple myeloma Treatment of relapsed and refractory multiple myeloma The Role of Immunotherapy in Multiple Myeloma American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Ce Immune Modulation in Hematologic Malignancies Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives Current and emerging treatment options for patients with relapsed myeloma New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)European perspective on multiple myeloma treatment strategies in 2014 Targeted therapy for HM1.24 (CD317) on multiple myeloma cells Evolving Paradigms in the Management of Multiple Myeloma: Novel Agents and Targeted Therapies Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab Smoldering multiple myeloma.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Treatment of multiple myeloma bone disease: experimental and clinical data.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.New strategies in the treatment of multiple myeloma.Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.New insights, recent advances, and current challenges in the biological treatment of multiple myeloma.GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.Profile of elotuzumab and its potential in the treatment of multiple myeloma Haematological malignancies: at the forefront of immunotherapeutic innovation.Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib.Multiple Myeloma: Treatment is Getting Individualized Alectinib, Ceritinib, Elotuzumab, and Venetoclax.Combination immune therapies to enhance anti-tumor responses by NK cells.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.Emerging biological insights and novel treatment strategies in multiple myeloma.Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?

P2860

Q26738944-D9158012-7DAE-48D3-A566-5AF8E83B6006 Q26740278-8C4CA2B8-398E-474A-B893-6EBD45D8BA51 Q26749180-2C260F6D-EF7F-4505-81B9-AEBDB732D1C7 Q26771144-79BCF23F-D3C0-4B6E-8B8E-7657D7AF9F81 Q26782868-9D997C3F-DD4B-4C0E-96FD-35D6E3844A03 Q26796307-BF153952-E354-4718-A5DD-CF22DB3EA43F Q26799104-1DEDEB40-414E-47A4-ABB5-9097E2E39FBF Q26830878-70E0BA0D-7A23-4A44-8487-9414773F136D Q27004421-D118612B-A0E5-4B3D-A549-946FE996700C Q27005966-06D17C05-5D30-404D-A602-DDD52DD1DA52 Q27026161-3A8DB5AE-4F40-4E8E-A8A5-DBAD050CACF9 Q27026478-A27FEC38-6EAA-4D93-B3A5-D62D4DAAFD66 Q28076147-9818BC7F-85E4-4A0D-B290-A33F6F2D0BEB Q28078993-00CFA04E-5D5C-4FF2-ADBF-8DC2A7889E99 Q28082855-48896CC4-2C30-4C44-98D6-35AEFE747DCA Q30249513-834C6880-A21F-4B76-AC27-6813124AACFB Q30275870-AB035EE8-AD8B-40A2-A299-AEF8B22865A4 Q30802505-523B64E0-F604-4FFE-B3B6-448AAE818A57 Q30868833-FD2F5F73-4A56-416D-A6DF-F53805617158 Q33403183-B3B48C1B-0471-40D1-81CD-F62A8D181C69 Q33414827-390C60A0-EECC-4947-9B72-25413D59D625 Q33441476-822D74C9-410A-4A32-AB03-2B10637251C3 Q33621610-FA2A90A4-DF2E-4D40-AC7C-46FEAA8DDB2D Q33958520-BB2DD883-7428-4C8C-806F-54CA68C5F2DE Q33992425-899641BD-2787-4B3D-B451-FCC28DC2E498 Q34380489-75F62EAD-8AE5-42AB-965B-4A8C10EBA3D2 Q34773850-63F439ED-09A3-43FB-93AF-73E9715EC712 Q35146307-1FE4CAF4-A140-47E7-8415-4587E6D7695A Q35628678-E5ACB7B1-887E-4C4E-9E9C-81B3258D8B2A Q35880618-7BB94CC0-9936-47D6-B104-A87DFBE636F2 Q36060298-6A084744-BB02-4571-9DDF-9D5F0A0E55F5 Q36522964-DA1FDE3F-5FDE-470B-BABB-B6AC9C210F68 Q37167686-D6C48429-9F75-4453-8EBE-83DF392190DD Q37408550-DAEF8ABE-0676-4731-BA90-F22276721989 Q37517482-A4BC0D84-A310-499B-AA3F-EAAF511F66BD Q37666309-E05ECBB0-264D-4217-BBEC-C58A0BBE9D37 Q37687119-A3EEDB1E-43A6-4964-88FF-D3B90DF2D987 Q37829230-18FB7233-28E9-441D-8836-A145D3AC0BDE Q38037600-336F16A1-0857-43EC-A3C1-CBA94886FFD6 Q38068534-8101803C-FD60-4444-AA22-4CC846C6A3F2

P2860

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma.

http://www.wikidata.org/entity/Q33401018

description

2012 nî lūn-bûn

@nan

2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Elotuzumab in combination with ...... r refractory multiple myeloma.

@ast

Elotuzumab in combination with ...... r refractory multiple myeloma.

@en

type

label

Elotuzumab in combination with ...... r refractory multiple myeloma.

@ast

Elotuzumab in combination with ...... r refractory multiple myeloma.

@en

prefLabel

Elotuzumab in combination with ...... r refractory multiple myeloma.

@ast

Elotuzumab in combination with ...... r refractory multiple myeloma.

@en

P1433

Q33401018-BE7B10BD-FC08-445A-BAB5-8B5963E92567

P1476

Q33401018-AC6B0BB8-C69E-4BFE-95ED-4D5E16BEAA5C

P2093

Q33401018-48A2817F-3315-4CF7-BE46-79C94046E016

Q33401018-60A793D2-ECC1-46EA-AEAC-7A68960AA5E0

Q33401018-60E77063-538C-4401-8E31-C2C141AC2AF2

Q33401018-65C967C9-71FB-4094-826D-669280D72831

Q33401018-7AE2BB3C-CACF-4748-8875-D46846B06E53

Q33401018-AE01A004-DDB3-4C3E-B778-A68FDD868E79

Q33401018-BF0B7A55-F3C4-44EF-BE3B-485DBD8B134F

Q33401018-F23A015B-EF0D-4EBF-9967-E129EE9C78E9

P304

Q33401018-B51F7CDB-AF27-4C67-8632-CB30A7B94EDC

P31

Q33401018-99B9693D-CC9C-4C25-8591-E03405B39C0B

P356

Q33401018-64E71846-0197-4E1E-B99E-A1874F5E67C8

P407

Q33401018-066FE4CA-DB56-44B9-85CD-66F3C41D0D8C

P433

Q33401018-CBB55A8A-BAF3-43F6-AC09-6584D3A5A1B5

P478

Q33401018-ADA53940-EF35-424D-B569-647A2830550B

P50

Q33401018-286906A7-1006-48E2-87F8-FE47751678CB

Q33401018-B28D94A2-CE12-49ED-86D5-AA05AC11DC42

Q33401018-BAB52CAE-0F30-4076-9D79-323D169DC3E2

Q33401018-DA2C290D-C13C-4AC1-BC58-A3A8DD2EED5E

P577

Q33401018-EDAA093E-B331-4934-8433-A10C478B8185

P698

Q33401018-653C603E-A13E-42EF-A870-5D47A1EC27E3

P921

Q33401018-6CF0B56E-E4E7-4071-BE61-37ABACEC6B0D

P356

JCO.2011.37.2649

P1433

Journal of Clinical Oncology

P1476

Elotuzumab in combination with ...... r refractory multiple myeloma.

@en

P2093

Amitabha Mazumder

http://www.w3.org/2001/XMLSchema#string

Anil K Singhal

http://www.w3.org/2001/XMLSchema#string

Christopher Westland

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Harousseau

http://www.w3.org/2001/XMLSchema#string

Jonathan L Kaufman

http://www.w3.org/2001/XMLSchema#string

L Claire Tsao

http://www.w3.org/2001/XMLSchema#string

Ravi Vij

http://www.w3.org/2001/XMLSchema#string

Sundar Jagannath

http://www.w3.org/2001/XMLSchema#string

P304

1953-1959

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2011.37.2649

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Philippe Moreau

P577

2012-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22547589

http://www.w3.org/2001/XMLSchema#string

P921